Pharma News

Hikma Pharmaceuticals and Glenmark Specialty S.A., a subsidiary of Glenmark Pharma launches Ryaltris in the US. It is a combination of olopatadine hydrochloride and mometasone furoate and formulated as a nasal spray. Ryaltris is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older.

Union Minister of Chemical and Fertilizers, Dr. Mansukh Mandaviya urges pharma industries to produce medicines and bring innovative research with the goal of ensuring good health and well-being of the people, not only for commercial purpose.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Heart attacks in women are more likely to be fatal than in men. The reasons are differences in age and in comorbidity burden which makes risk assessment in women a challenge. Researchers at the University of Zurich have now developed a novel artificial-intelligence-based risk score that improves personalized care for female patients with heart attacks.

A study of mice found that dietary sugar alters the gut microbiome, setting off a chain of events that leads to metabolic disease, pre-diabetes, and weight gain.

The findings, published today in Cell(link is external and opens in a new window), suggest that diet matters, but an optimal microbiome is equally important for the prevention of metabolic syndrome, diabetes, and obesity.
Diet alters microbiome.

The Japan health Ministry has approved Evusheld of AstraZeneca for COVID-19. Evusheld is an investigational medicine used in adults and adolescents for pre-exposure prophylaxis for prevention of COVID-19.

In December 2021, the U.S. Food and Drug Administration had approved AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together)for emergency use for prophylaxis of COVID-19. And followed by March 2022, EMA's human medicines committee (CHMP) has recommended granting a marketing authorisation for Evusheld.

​​The US government said yesterday that it would provide about USD 11 million to support the packaging of Jynneos monkeypox vaccine at a U.S. based manufacturers facility, as reported by Reuters.​

Assam based Association of Advanced Pharmacy Practitioners (AAPP) decides that they will not participate in the forthcoming World Pharmacist Day celebration programme on 25th September as a mark of resentment over the issue of not maintaining uniform standard of national eligibility in Pharmacy admission procedure.

A three-drug medication known as a polypill, developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.  These are findings from the SECURE trial led by Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of CNIC.